ALFASIGMA S.P.A.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 68187
 
  
 
C07D HETEROCYCLIC COMPOUNDS 26136
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 689
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 594
 
  
 
C07K PEPTIDES 4132
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4202
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 346
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 3122
 
  
 
A23L FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT 262
 
  
 
A61B DIAGNOSIS; SURGERY; IDENTIFICATION 2238

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0112,791 SOLID FORMULATIONS CONTAINING OMEGA-3 AND RESVERATROLMar 26, 15Apr 27, 17[A61K]
2017/0071,916 PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN, PROCESSES FOR THEIR OBTAINMENT AND METHOD OF TREATING INTESTINAL DISEASEApr 15, 16Mar 16, 17[A61K]
2016/0310,458 COMPOUNDS USEFUL FOR INCREASING NEUROGENESIS IN NEURAL TISSUEMay 19, 16Oct 27, 16[A61K]
2016/0303,206 PHARMACEUTICAL OR NUTRITIONAL COMPOSITIONS CONTAINING GALACTOSIDASE, AND THEIR USEJun 27, 16Oct 20, 16[A61K]
2014/0308,350 NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMSApr 11, 14Oct 16, 14[A61K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9872831 Pharmaceutical composition of oxidised avidin suitable for inhalationJul 25, 12Jan 23, 18[A61K, B82Y]
9725466 Rifaximin derivative and uses thereofMay 16, 16Aug 08, 17[A61K, C07D]
9546401 Assays and methods for selecting a treatment regimen for a subject with depressionMar 12, 13Jan 17, 17[A61K, C12Q, C12P]
9540691 Assays and methods for selecting a treatment regimen for a subject with depressionMar 07, 13Jan 10, 17[A61K, C12Q, C12P]
9498442 Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effectApr 24, 14Nov 22, 16[A61K, C07D]
9457037 Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiencySep 19, 13Oct 04, 16[A61K]
9452157 Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereofJul 03, 13Sep 27, 16[A61K, C07D, G01N]
9402885 Method of treating GERD with alpha and beta galactosidasesJul 11, 14Aug 02, 16[A61K]
9364467 Rifaximin derivative and uses thereofMay 08, 15Jun 14, 16[A61K, C07D]
RE45968 Vector for efficient selection and/or maturation of an antibody and uses thereofMar 14, 13Apr 12, 16[C07H, C12P, C12N]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0210,757 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMINAbandonedSep 01, 16Jul 27, 17[C07D]
2017/0210,758 POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMINAbandonedSep 02, 16Jul 27, 17[C07D]
2016/0058,766 ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH DEPRESSIONAbandonedAug 25, 15Mar 03, 16[A61K, C12Q]
2014/0186,450 GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINAbandonedDec 04, 13Jul 03, 14[A61K]
2005/0107,470 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermiaAbandonedJan 07, 05May 19, 05[A61K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.